| 0.841 0.146 (21.06%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1 |
1-year : | 1.17 |
| Resists | First : | 0.86 |
Second : | 1 |
| Pivot price | 0.72 |
|||
| Supports | First : | 0.66 |
Second : | 0.54 |
| MAs | MA(5) : | 0.71 |
MA(20) : | 0.73 |
| MA(100) : | 0.86  |
MA(250) : | 0.82 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 44.6 |
D(3) : | 25.1 |
| RSI | RSI(14): 63.8 |
|||
| 52-week | High : | 3.78 | Low : | 0.28 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ KTTA ] has closed Bollinger Bands are 34.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.86 - 0.86 | 0.86 - 0.87 |
| Low: | 0.68 - 0.69 | 0.69 - 0.69 |
| Close: | 0.84 - 0.84 | 0.84 - 0.85 |
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Tue, 28 Apr 2026
KTTA Stock Price, Quote & Chart | PASITHEA THERAPEUTICS CORP (NASDAQ:KTTA) - ChartMill
Wed, 22 Apr 2026
Funicular Funds (KTTA) reports 1.84M shares, 7.4% stake in Pasithea (KTTA) - Stock Titan
Fri, 17 Apr 2026
Coastlands Capital reveals KTTA (NASDAQ: KTTA) stake in shares and pre-funded warrants - Stock Titan
Fri, 10 Apr 2026
Pasithea Therapeutics Corp. (KTTA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 25 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 69.9 (%) |
| Shares Short | 122 (K) |
| Shares Short P.Month | 174 (K) |
| EPS | -2.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.39 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.4 % |
| Return on Equity (ttm) | -58.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.29 |
| PEG Ratio | 0 |
| Price to Book value | 0.35 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|